Researchers are testing the drug, a PEGylated recombinant human hyaluronidase enzyme, in combination with standard-of-care gemcitabine and nab-paclitaxel (Abraxane) in patients with stage IV treatment-naïve pancreatic cancer whose tumors express high levels of hyaluronan (HA). PEGPH20 degrades HA, a carbohydrate that can build up in the tumor microenvironment and block the delivery of anticancer therapies. Read more . . .
PEGPH20 (pegvorhyaluronidase alfa), a novel formulation of a naturally occurring enzyme, is being investigated as a biomarker-driven treatment for patients with advanced pancreatic cancer.